PDCD1LG2 and melanoma: Moreover, our survey identified a differentially methylated side (Supplementary Table 4) within the promoter of PD-L2 (PDCD1LG2) that may predict progression-free survival in melanoma patients receiving anti-PD-1 immunotherapy [28].